<DOC>
	<DOCNO>NCT00267683</DOCNO>
	<brief_summary>This trial conduct Japan . This clinical trial study efficacy safety thrice daily Insulin Aspart compare Glibenclamide type 2 diabetic patient .</brief_summary>
	<brief_title>Efficacy Safety Insulin Aspart Versus Glibenclamide Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Type 2 diabetes Diet therapy least 12 week , diet therapy oral hypoglycaemic agent ( ) SU agent least 12 week No previous treatment insulin and/or SU agent HbA1c 7.5 % 10.0 % Body Mass Index ( BMI ) 30.0 kg/m2 Proliferative retinopathy maculopathy require acute treatment Impaired hepatic function Impaired renal function Cardiac diseases Uncontrolled hypertension Known hypoglycaemia unawareness recurrent major hypoglycaemia Current treatment systemic corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>